Is MAIA Biotechnology going out of business?

MAIA Biotechnology, Inc. (MAIA) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

MAIA Biotechnology, Inc. (MAIA) fundamentals, assembled from SEC filings.

Five questions, kept separate

Survival - Critical

Under 1 mo of estimated runway from 2026-06-30, based on $0.0 of cash and short-term investments against $36.2M of annual burn. Adjusted shares outstanding increased 83.0% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Evidence incomplete

The current price is available, but the filing does not contain enough applicable valuation evidence to interpret it.

Event risk - No active asserted risk

No active asserted adverse event was found in the available filing evidence. This is not proof that no unclassified event exists.

What the rules read

• Shares dilution YoY: 83.01% (YoY)
• Return on Assets: -79.31%
• Price / Earnings: Unprofitable (see Valuation)
• Effective Tax Rate: 0.00% (loss-making)

Read from filings through 2026-08-10.

Price as of 2026-09-09.